1 / 10

Autoinducer of Virulence As a Target for Vaccine and Therapy Against Staphylococcus aureus

Autoinducer of Virulence As a Target for Vaccine and Therapy Against Staphylococcus aureus. Vasiliki Papadimitriou Seminar February 21, 2000. Purpose and Rationale. To find a new approach to treating and vaccinating S. aureus infections via autoinducer of virulence

dixon
Download Presentation

Autoinducer of Virulence As a Target for Vaccine and Therapy Against Staphylococcus aureus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Autoinducer of Virulence As a Target for Vaccine and Therapy Against Staphylococcus aureus Vasiliki Papadimitriou Seminar February 21, 2000

  2. Purpose and Rationale • To find a new approach to treating and vaccinating S. aureus infections via autoinducer of virulence • Motive behind finding a new approach is due to the development of drug-resistant bacteria

  3. Profile of S. aureus • Gram-positive pathogenic bacteria • responsible for: • toxic shock syndrome • septicemia • meningitis • endocarditis • pneumonia • enterotoxins • hemolysins

  4. Regulation of S. aureus • By regulatory RNA molecule, RNA III (encoded by agr locus) • autoinduced by RAP (RNA III activating protein) • only active at a threshold concentration • inhibited by RIP (RNA III inhibiting protein) • produced by a non-pathogenic bacteria mutated by nitrosoguanidine • Known not to be determined by the any codes of genes such as agr ( as shown in following experiment)

  5. Experiment • Replaced an agr-null strain with a tetM marker • Used murine model of cutaneous infection to test if S. aureus can be inhibited by using RAP to immunize • Determination of antibody development by immunoblotting and binding activity

  6. Inhibition of RAP by RIP and Pep

  7. RAP is independent of agr locus

  8. Results • RAP and RAP* had no real comparable differences in suppression of SD cells, however, were significantly more effective than the control CFA • According to Table 1, RIP has an immune effect in mice but has a smaller effect when almost double the amount of SD cells are used • After treating SD cells with Pep and RIP, in comparison with the controls of saline and DMSO, Pep had a significantly better effect on suppressing SD cells

  9. Results (cont’d) • Those treated with the RAP vaccine had developed antibodies • Controls did not develop antibodies • Some mice had preimmune antibodies to RAP • refer to Table 1 for discussion

  10. Conclusion • Pep had significant suppressive effects on SD cells at a high concentration • This ratio between the amount of bacteria and synthetic RIP helps determine the effectiveness of the host to fight the infection, and even more important the toxicity • Scientist believe this technique is potentially one of the new approaches to avoid the increased bacteria resistance to antibiotics

More Related